SCHEMBL24263134

SCHEMBL24263134

O=C(NC1CCc2n[nH]c(=O)cc2C1)c1ccc(I)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 7/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
GAA P10253 1/20 0.38
NAMPT P43490 1/20 0.37
CRBN Q96SW2 1/20 0.37
HDAC8 Q9BY41 2/20 0.36
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24263090 0.89 NPC1 (0.47) SMYD3TSHRTMEM97SIGMAR1GAA
SCHEMBL24263128 0.89 RAB9A (0.47) SMYD3CYP1A2TSHRCYP2C19GAA
SCHEMBL24263131 0.89 HDAC8 (0.45) SMYD3GAANAMPTHDAC8KMT2A
SCHEMBL24263129 0.89 HDAC8 (0.48) SMYD3HDAC8NPC1RAB9AMEN1
SCHEMBL24263127 0.88 MTNR1A (0.46) GAACRBNHDAC8MTNR1AMTNR1B
SCHEMBL24263084 0.87 KMT2A (0.42) SMYD3TSHRMAPK1GAANAMPT
SCHEMBL24263089 0.86 KDM5A (0.40) SMYD3CRBNHDAC8NPC1RAB9A
SCHEMBL24263197 0.86 TAOK1 (0.48) SMYD3GAACRBNMEN1KMT2A
SCHEMBL24263227 0.85 HDAC8 (0.42) CYP1A2TSHRMAPK1CYP2C19GAA
SCHEMBL24263079 0.84 TAOK1 (0.40) SMYD3TMEM97SIGMAR1GAACRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022040508-A1 COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2022-02-24 WO disclosed